Home
Sign In
About
Curriculum
Activity Information
Target Audience
Learning Objectives
Technical Requirements
The Curriculum in Iron Metabolism & Related Disorders is supported by an educational grant from
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Course materials have been developed for use outside of the United States.
|
 |
|
|
|
|
|
|
Indications for Successful Iron Overload Treatments and Monitoring: Other Anaemias
In this webcast, Dr. Inati discusses rare anaemias, including Diamond-Blackfan anaemia, Fanconi’s anaemia, sideroblastic anaemia, congenital dyserythropoietic anaemia, and dyskeratosis congenita, with an emphasis on the identification and treatment of iron overload in patients with these disorders.
|
|
Faculty
|
|
|
Adlette C. Inati, MD
Head
Division of Pediatric Hematology-Oncology
Medical Director
Children's Center for Cancer and Blood Diseases
Rafik Hariri University Hospital
Beirut, Lebanon
|
|
|
Target Audience
This activity is designed for haematologists, medical oncologists, haematology-oncology specialists, and other healthcare professionals involved in the screening, evaluation, treatment, and management of adults and children with iron overload, resulting from the spectrum of chronic iron overload diseases.
|
Learning Objectives
After participating in this activity, participants should be better able to:
- Based on the diagnostic criteria for Diamond-Blackfan anaemia, Fanconi’s anaemia, sideroblastic anaemia, congenital dyserythropoietic anaemia, and dyskeratosis congenita, identify patients with these rare anaemias so that effective treatment of the underlying disorder can be initiated.
- Using measures such as serial ferritin levels, liver iron concentration, and cardiac iron load, monitor your patients with rare anaemias for iron overload, and institute iron chelation therapy according to current recommendations for beginning treatment.
- Based on the efficacy/toxicity profiles and drug regimens of available iron chelators, determine the most appropriate iron chelation therapy to prevent/reduce iron toxicity and facilitate compliance in your patients with rare anaemias.
|
Disclosure Information
Adlette C. Inati, MD, has no significant relationships to disclose.
|
|
|
|
|
|
|
